Ibrance, Pfizer breast cancer drug shows impressive results

April 16, 2015 4:59 AM

21 0

Pfizer’s breast cancer drug, Ibrance clinical trial was delayed due to some efficacy issues based on the assessment of independent Data Monitoring Committee (DMC), but after the issues have been solved the clinical trial was continued.

Ibrance also known as palbociclib, the breast cancer drug is undergoing phase 3 study called PALOMA-3 trial and it has met its primary ends and showed improvements in Progression-Free Survival of PFS.

Read more

To category page